Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eversource Energy (D/B/A) Common Stock (ES) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Eversource Energy (D/B/A) Common StockTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Eversource Energy (D/B/A) Common Stock vs IDEXX Laboratories, Inc. — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $67 (market cap $25.11B), while IDEXX Laboratories, Inc. trades at $532.96 (market cap $41.68B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.72% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and IDEXX Laboratories, Inc. for 47 Days on average.

ESIDXX
Market Cap
$25.11B$41.68B
Volume
3,164,400824,427
Sector
UtilitiesHealth
52-Week High
$76.21$766.68
52-Week Low
$63.28$504.70
Typical Hold Time
0 Days47 Days
Enterprise Value
$55.18B$42.58B
Dividend Yield
4.72%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eversource Energy (D/B/A) Common Stock

Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.

ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $520.31, down 0.69% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.27 versus $3.94, maintaining a 3-quarter beat streak. Revenue growth accelerated to $4.3B in 2025 with robust 25.03% net margins and exceptional 74.21% ROE. Recent acquisitions like CoVetAI expand veterinary workflow capabilities while management reaffirmed long-term growth targets at the Morgan Stanley Healthcare Conference.

Wall Street maintains bullish sentiment with 56.5% buy ratings and $665 consensus target implying 28% upside. Strong profitability and diagnostic innovation pipeline support growth, though elevated P/E of 37.2 and recent insider selling pose valuation concerns. Key risks include FX headwinds, weaker U.S. vet visits, and competitive pressures in veterinary diagnostics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ES
100% Buy0% Sell
Avg holding period · 0 Days
IDXX

No sentiment data available yet.

About Eversource Energy (D/B/A) Common Stock

Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.

Read more on ES →

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →